Amyotrophic Lateral Sclerosis
Conditions
Keywords
ALS, Stem cells, Growth Factor, Regenerative, Neural Progenitor Cells, NPC, Transplantation
Brief summary
The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neural cell. The growth factor is called glial cell line-derived neurotrophic factor, or GDNF. GDNF is a protein that promotes the survival of many types of neural cells. Therefore, the cells are called CNS10-NPC-GDNF. The investigational treatment has been tested in people by delivering it to the spinal cord. However, it has only been delivered to the motor cortex of animals. In this study, we want to learn if CNS10-NPC-GDNF cells are safe to transplant into the motor cortex (brain) of people.
Detailed description
This study will be the first to use a genetically modified progenitor cell line delivered to the motor cortex to treat a neurodegenerative disease. This is a Phase 1/2a, single-center, safety study of two escalating doses of human neural progenitor cells expressing GDNF (CNS10-NPC-GDNF) delivered unilaterally to the hand-knob area of the motor cortex of patients with ALS. Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of three sequential dosing groups. Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. Primary Outcome: Safety, as evaluated by: * Adverse Events and Serious Adverse Events * Post-op MRI and/or CT (with contrast) and as clinically indicated
Interventions
BIOLOGICALCNS10-NPC-GDNF
Unilateral injections of CNS10-NPC-GDNF into the motor cortex
Sponsors
California Institute for Regenerative Medicine (CIRM)
Cedars-Sinai Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion: 1. Confirmed diagnosis of ALS (Possible, Lab-supported Probable, Probable or Definite El Escorial Criteria) 2. Duration of ALS symptoms ≤ 36 months 3. Progressive weakness in upper extremities, with EMG supported evidence of denervation in both upper extremities 4. Forced Vital Capacity ≥50% of predicted normal in supine 5. Age: 18 years or older 6. Able to provide Informed Consent 7. Be geographically accessible to the study site and able to travel to study site for required visits 8. Have caregiver to assist in the transportation and care required by participation in the study 9. Not taking riluzole and/or edaravone or on a stable dose for ≥ 30 day 10. For women of child bearing capacity, negative pregnancy test prior to surgery and willingness to use birth control for the duration of the trial. 11. Medically able to undergo craniotomy as determined by the site PI and/or investigators 12. Medically able to tolerate the immunosuppression regimen as determined by the site PI Exclusion: 1. Using invasive ventilatory assistance 2. Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI 3. Presence of any of the following conditions: 1. Current drug or alcohol abuse 2. Any known immunodeficiency syndrome 3. Unstable medical condition 4. Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening 4. Persons of child bearing capacity not willing to practice birth control 5. Receiving any investigational device/biologic/drug in the past 30 days or any previous exposure to stem cell therapy 6. Any condition in the upper extremities that precludes serial strength or coordination testing 7. Any condition that the investigators feel may pose complications for the surgery 8. Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints 9. Allergy to Beta-Lactam antibiotics 10. Donor Specific Antibodies (DSA) ≥ 2500MFI or CPRA ≥ 20% 11. Contraindications to MRI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety, as evaluated by the incidence of Adverse Events and Serious Adverse Events and their relationship to the treatment | 12 months post-operatively |
| Safety, as evaluated by changes from baseline in the brain MRI | 12 months post-operatively |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hand/Wrist Strength | Hand/Wrist strength testing will be performed 7 times over 15 months | Change from baseline for Hand/Wrist strength using Hand-held dynamometer |
| Compound Motor Action Potential (CMAP) | CMAP will be performed 7 times over 15 months | Change from baseline for CMAP |
| Force Generation via Accurate Test of Limb Isometric Strength (ATLIS) testing | ATLIS testing will be performed 7 times over 15 months | Change from baseline for force generation by ATLIS |
| Penn Upper Motor Neuron Score (PUMNS) | PUMNS will be performed 7 times over 15 months | Change from baseline for Penn Upper Motor Neuron Score. (Scale of 0-32, where 0 is normal) |
| Hand Knob - Functional MRI (fMRI) | fMRI will be performed up to 4 times over 15 months | Changes from baseline in brain activity in the hand knob area evaluated by fMRI |
| Functional Hand assessments using 9-hole peg test | 9-hole peg testing will be performed 7 times over 15 months | Change from baseline for 9-hole peg test |
| Pinch Strength | Pinch Strength testing will be performed 7 times over 15 months | Change from baseline for pinch strength |
Countries
United States
Outcome results
None listed